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Abstract 
Pancreatic cancer is the fourth leading cause of cancer death in western countries with more than 
100,000 new cases per year in Europe and a mortality rate higher than 90%. In this scenario, 
advanced therapies based on gene therapies are emerging, thanks to a better understanding of 
tumour architecture and cancer cell alterations. We have demonstrated the efficacy of an innovative 
approach for pancreatic cancer based on mesenchymal stromal cells (MSC) genetically engineered 
to produce TNF-related Apoptosis Inducing Ligand (TRAIL). Here we investigated the combination 
of this MSC-based approach with the administration of a paclitaxel (PTX)-based chemotherapy to 
improve the potential of the treatment, also accounting for a possible resistance onset. 
Methods: Starting from the BXPC3 cell line, we generated and profiled a TRAIL-resistant model of 
pancreatic cancer, testing the impact of the combined treatment in vitro with specific cytotoxicity 
and metabolic assays. We then challenged the rationale in a subcutaneous mouse model of 
pancreatic cancer, assessing its effect on tumour size accounting stromal and parenchymal 
organization. 
Results: PTX was able to restore pancreatic cancer sensitivity to MSC-delivered TRAIL by 
reverting its pro-survival gene expression profile. The two compounds cooperate both in vitro and in 
vivo and the combined treatment resulted in an improved cytotoxicity on tumour cells. 
Conclusion: In summary, this study uncovers the potential of a combinatory approach between 
MSC-delivered TRAIL and PTX, supporting the combination of cell-based products and 
conventional chemotherapeutics as a tool to improve the efficacy of the treatments, also addressing 
possible mechanisms of resistance. 
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Introduction 
Pancreatic cancer is the fourth leading cause of 
cancer death in western countries characterized by 
more than 100,000 new cases per year in Europe and a 
mortality rate higher than 90% [1]. Although there has 
been some progress in the use of improved diagnostic 
methods and development of novel targeted thera-
pies, the overall survival rate has not improved over 
the last decade with a 5-year survival rate settled 
around 8% [2,3]. Among the most important factors 
contributing to this inauspicious outcome, a pivotal 
role is played by late stage diagnosis, the abundant 
stromal component and a frequent relapse even after 
resection [4]. Moreover, intrinsic or acquired drug 
resistance often characterizes pancreatic cancer and its 
treatment remains a major challenge demanding 
novel, more effective therapies also accounting for the 
robust desmoplastic reaction that reduces drug 
bioavailability inside pancreatic cancer [5]. 
In the settings of locally advanced or metastatic 
pancreatic cancer, even in the presence of modest 
improvements in survival, newer standard treatments 
have become available, such as systemic chemothe-
rapy with FOLFIRINOX or gemcitabine alone or in 
combination with the promising Nab-Paclitaxel [6,7]. 
In particular, Paclitaxel (PTX) is a microtubule- 
stabilizing agent belonging to the family of Taxanes. 
The potent suppression of microtubule dynamics 
ultimately leads to cell death [8,9]. Currently, PTX is 
administered in a Nanoparticle Albumin Bound (Nab) 
formulation, improving its solubility in water and 
also its bioavailability, thanks to the albumin-specific 
receptors on the cell membrane binding Nab-PTX 
particles and transporting them into the cell by 
transcytosis. Another key mechanism resulting in 
drug accumulation is the enhanced perfusion of 
Nab-PTX through endothelial gaps in tumour 
vasculature and its retention inside the stroma as key 
element to be additionally considered for more 
effective treatments [10,11].  
Stromal cells in cancer are increasingly consid-
ered as targets of pre-clinical and clinical research. In 
this scenario, cell and gene therapies are emerging as 
tools to manipulate tumour microenvironment, 
thanks to a better understanding of the cross-talks 
between cancer cells and stromal elements [12]. 
Among non-immune gene-modified effectors, mesen-
chymal stromal/stem cells (MSC) have been studied 
for their possible use as tumour-specific delivery 
vehicles for therapeutic compounds, suicide genes 
and oncolytic viruses. Their tropism for tumours and 
metastases has been exploited to transform MSC by 
genetic manipulation, in bullets capable of delivering 
biological agents to the tumour site [13]. MSC have 
been engineered for the production of several 
compounds such as interleukins, interferons, pro- 
drug converting enzymes, oncolytic viruses, anti-miR, 
anti-angiogenic agents and pro-apoptotic molecules 
such as TNF-related Apoptosis Inducing Ligand 
(TRAIL) with pre-clinical and clinical promising 
results [13–16]. 
Our group sought to introduce MSC as delivery 
approach to selectively direct TRAIL variants against 
the tumour, empowering its anti-cancer activity and 
overcoming its poor bioavailability [17–19]. TRAIL- 
expressing gene-modified MSC can reach and engraft 
into tumour burden effectively delivering the 
anti-cancer agent. Their efficacy has also been 
demonstrated by others in in vivo models of lung, 
colon-rectal, breast, cervical, brain tumours with 
pro-apoptotic effects [20–24]. While this strategy has 
potential, there are several aspects that will need to be 
optimized, such as MSC homing, persistence and the 
possible resistance to MSC delivering a single drug, 
especially for cancers that are not particularly 
chemo-sensitive.  
Recent findings suggest that successful treat-
ments for pancreatic cancer may proceed through the 
combination of conventional chemo- and radio- 
therapy with cell and gene approaches, originating 
novel therapeutic concepts in order to achieve a 
greater efficacy and deal with resistance mechanisms 
[25,26]. In this perspective, we previously demonst-
rated in vitro that a combinatory treatment with MSC 
expressing TRAIL and bortezomib resulted in the 
sensitization of a TRAIL-refractory breast cancer cell 
line [27]. Moreover, other drugs such as valproic acid, 
anisomycin, doxorubicin, trifluorothymidine and 
decitabin revealed TRAIL-sensitizing properties in 
several tumour models [28]. However, there is little 
consensus on how different chemotherapeutics 
synergize with TRAIL signalling to mediate enhanced 
tumour cell death, with various studies showing 
upregulation of TRAIL receptors, downregulation of 
anti-apoptotic genes and enhanced grouping of 
TRAIL receptors on the membrane as being important 
for the combination effect. Moreover, sustained 
activation of the NFκB pathway can suppress TRAIL- 
mediated apoptosis through the upregulation of 
cFLIP, IAP and Bcl2 family proteins. Accordingly, 
agents that directly or indirectly suppress NFκB, 
cFLIP and IAP activity have been shown to strongly 
synergize with activators of the TRAIL pathway in 
vitro and in vivo [29]. Even if PTX mechanism of action 
has not been completely elucidated, it involves the 
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downregulation of NFkB and Bcl2 [30,31] and has 
been successfully employed to sensitize gastric cancer 
cells to TRAIL [32]. For these reasons and accounting 
its role as a standard of care in pancreatic cancer, it 
can be considered as a possible combinatory player 
with TRAIL-delivering strategies. 
Starting from an early study demonstrating the 
capacity of a MSC membrane bound form of TRAIL to 
target pancreatic cancer [19], relying on adipose- 
derived MSC delivering a novel soluble TRAIL 
variant [17,33] and additionally accounting the risk of 
TRAIL-resistant cancer, we originally combined a 
cell-based approach with the administration of 
PTX-based schedule. To explore the possible TRAIL- 
sensitizing role of Nab-PTX, the efficacy of the 
combined treatment was assessed in a laboratory- 
generated model of TRAIL-resistant pancreatic cancer 
both in vitro and in vivo. 
Materials and Methods 
Tissue culture 
AD-MSC were obtained as previously described 
from lipoaspirate specimens of individuals undergo-
ing liposuction for aesthetic purposes after approval 
by local Ethical Committee [27]. Cells were cultured in 
αMem (Gibco, Thermo Fisher Scientific Inc., Waltham, 
MA, USA) supplemented with 2.5% human platelet 
lysate (Modena Blood Bank, Policlinic of Modena, 
Modena, Italy), 1% L-glutamine (BioWhittaker, Lon-
za, Verviers, Belgium), 0.5% ciprofloxacin (Fresenius 
Kabi Italia S.r.l., Verona, Italy) and 1 IU/mL heparin 
(Sigma Aldrich, St. Louis, MO, USA). BXPC3 cells 
(Interlab Cell Line Collection, ICLC, Genova, Italy), 
instead, were maintained in RPMI (Gibco) integrated 
with 10% FBS, 1% L-glutamine and 1% penicillin/ 
streptomycin (all from Carlo Erba Reagents Srl). 
Authentication of BXPC3 cells was performed last 
year by Leibniz-Institut DSMZ GmbH (Braunschweig, 
Germany). 
Establishment of sTRAIL-resistant BXPC3 cell 
lines 
Supernatants conditioned by AD-MSC secreting 
soluble TRAIL (AD-MSC sTRAIL) were produced as 
previously reported [17,33]. Briefly, when AD-MSC 
sTRAIL reached almost 80% confluence, culture 
medium was replaced with BXPC3 maintenance 
medium. After 48 hours, conditioned supernatant was 
collected, filtered through 0.45 µm PES low binding 
protein filter (Corning Incorporated, NY, USA) and 
stored at -80°C until use. Conditioned medium from 
AD-MSC infected with an empty vector (AD-MSC 
EMPTY) was collected in the same way and used as 
control. 
Development of sTRAIL-resistant BXPC3 cell 
lines has been pursued by two distinct approaches 
(Figure 1A). A pulsed strategy, resembling the 
chemotherapy cycles, consisted in exposing cultured 
BXPC3 to sTRAIL-containing supernatant for 24 h 
once weekly with surviving cells allowed to recover in 
complete medium until the subsequent hit. In an 
additional strategy, a continuous treatment was 
introduced and cells were constantly maintained in 
sTRAIL-containing supernatant. To quantify the 
resistance gain, cells were seeded at the established 
time points in 12-well multiwell plates at 6000 
cells/cm2 and incubated on the following day with 
sTRAIL-containing supernatant for 24 h. Death rate 
was assessed by FACS following Propidium Iodide 
(PI) staining. Supernatant deriving from AD-MSC 
EMPTY was used as control. Wild type (WT) BXPC3 
were evaluated for comparison. After selection, 
BXPC3 clones were characterized for resistance to a 
range of recombinant human TRAIL (rhTRAIL) 
concentrations by MTS, FACS, microarray analysis 
and qRT-PCR. 
ELISA  
sTRAIL levels from AD-MSC supernatants were 
measured by Quantikine Human TRAIL/TNFSF10 kit 
(R&D Systems, Inc, Minneapolis, MN, USA) 
according to manufacturing instructions. At least 4 
supernatants from different cell cultures were 
analysed in duplicate. 
MTS metabolic assay 
In the MTS assay (CellTiter 96 AQueous One 
Solution Cell Proliferation Assay, Promega Corpora-
tion, Madison, WI, USA), for each tested sample and 
condition, 5000 cells were seeded in a 96-wells plate. 
The following day, medium was replaced with 
sTRAIL-containing supernatant or AD-MSC EMPTY 
conditioned medium containing the appropriate 
concentration of rhTRAIL/Apo2 Ligand (rhTRAIL, 
Peprotech Inc., Rocky Hill, NJ, USA) (10, 20, 50, 100, 
200, 500, 1000 and 10,000 ng/mL). After 24 h, the plate 
was analysed with Multiskan FC Microplate 
Photometer (Thermo Fisher Scientific Inc.) according 
to the manufacturer’s recommendations. 
FACS analyses 
The expression of TRAIL functional receptors 
(DR4 and DR5) and decoy receptors (DcR1 and DcR2) 
was assessed by flow cytometry and compared with 
wild type BXPC3 cells. Briefly, cells were aliquoted in 
FACS analyses polypropylene tubes (VWR Interna-
tional, Radnor, PA, USA) and incubated in 100 μL 
blocking buffer composed of Dulbecco’s Modified 
Eagle Medium (Gibco), 10% FBS, 0.1 M Sodium Azide 
and human immunoglobulin G (both from Sigma 
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Aldrich) for 20 min on ice. After a washing step, cells 
were resuspended in PBS with 0.5% Bovine Serum 
Albumin (BSA, Sigma Aldrich) and stained on ice and 
in the dark for 30 min with the following monoclonal 
antibodies: PE-anti-DR4, APC-anti-DR5, PE-anti- 
DcR1 (all from BioLegend, San Diego, CA, USA), 
APC-anti-DcR2 (R&D Systems, Minneapolis, MN, 
USA). In all the experiments, the corresponding 
isotype-matched antibodies were used as negative 
controls (provided by BD Biosciences, San Diego CA, 
USA and BioLegend). 
PI staining was done at the final concentration of 
50 µg/mL (stock solution 1 mg/mL in PBS, Sigma 
Aldrich) and incubation proceeded at 37°C in the dark 
for 30 min. Cells and supernatants from each well 
were centrifuged for 10 min at 1400 rpm and 
resuspended in 100 µL of 1x Annexin V Buffer 
Solution containing APC-Annexin V antibody (both 
from BD Biosciences). Data were collected using a 
FACS Aria III flow cytometer (BD Biosciences) and 
analysed on FACS Diva software (BD Biosciences). 
 
 
Figure 1. Generation of BXPC3 clones resistant to sTRAIL and rhTRAIL. (A) Representation of the selection strategy. Wild type BXPC3 were treated with sTRAIL- 
containing supernatant once a week for 10 weeks (pulsed selection), obtaining PA and PB clones, or constantly for 10 weeks (continuous selection), obtaining CA and 
CB clones. (B) Wild type BXPC3 and selected clones were tested for susceptibility to sTRAIL treatment by MTS assay. Each bar represents metabolic inhibition 
respect to untreated control. (C) rhTRAIL dose-response assay for wild type and selected BXPC3 clones in MTS. Cells were treated with a range of concentrations 
of rhTRAIL for 24 h. (D) Expression of TRAIL functional (DR4, DR5) and decoy (DcR1, DcR2) receptors by flow cytometry on wild type and selected BXPC3 clones. 
(E) qPCR analysis on PA clone for the expression of key pro-survival genes respect to BXPC3 wild type cells. Data are represented as mean±SD. All data are represented 
as the mean of two independent experiments performed in triplicate. WT: Wild type BXPC3; CA, CB, PA, PB: selected BXPC3 clones. * p<0.01, ** p<0.001, *** p<0.0001 
with Student’s T-test. § p<0.05, ^ p<0.0001, ° p<0.0001 by ANOVA and multiple comparison test. 
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Microarray and qRT-PCR analyses 
A whole transcriptome microarray analysis was 
performed by the facility of Consorzio Futuro in 
Ricerca (University of Ferrara, Ferrara, Italy) on the 
most TRAIL-resistant clone (defined as BXPC3 PA) in 
comparison with parental BXPC3 WT cells (Agilent 
SurePrint G3 Human Gene Expression v3 8x60K 
Microarray Kit #G4851C, Agilent Technologies, Palo 
Alto, CA). A subset of differentially expressed key 
genes involved in death ligand-induced apoptosis 
resistance was identified and included BCL-XL, 
cFLIP, XIAP, NFKB1 and NFKB2 genes. Differential 
expression of these genes was then analysed by 
qRT-PCR before and after PTX treatment (50 ng/mL 
for 24 h, Paclitaxel, Accord Healthcare Italia S.r.l., 
Milan, Italy). In detail, total cellular RNA was isolated 
from wild type and BXPC3 PA, using Trizol reagent 
(Invitrogen Corporation, Carlsbad, CA, USA) and 
quantified by spectrophotometry using a DU730 
UV/VIS Spectrophotometer (Beckman Coulter, Brea, 
CA, USA). A 2 µg of template was reverse-transcribed 
into cDNA by the RevertAid H minus first-strand 
cDNA synthesis kit (Fermentas, Waltham, MA, USA) 
using Veriti 96-Well Thermal Cycler (Applied 
Biosystems, Foster City, CA, USA). 
qPCR was performed with Fast SYBR Green 
Master Mix (Applied Biosystems) using Step One 
Real-Time PCR System Thermal Cycling Block 
(Applied Biosystems). The program ended with melt 
curve analysis to check specificity of amplification. 
Levels of mRNA for tested genes were compared 
using ∆∆CT method with β-Actin and GAPDH as 
reference genes. All primers were purchased from 
Integrated DNA Technologies (Coralville, IA, USA) 
and the sequences are shown in Table 1. Data have 
been analysed using StepOne software (version 2.3, 
Life Technologies Corporation, Carlsbad, CA, USA). 
Table 1. Primers sequences for qPCR 
Gene Primers sequences 
BCL-XL FW: GTG GAA AGC GTA GAC AAG GAG 
RV: CTG CAT TGT TCC CAT AGA GTT C 
cFLIP FW: CCT CAC CTT GTT TCG GAC TAT AG 
RV: TCC TTG CTT ATC TTG CCT CG 
XIAP FW: CTT GGA CCG AGC CGA TC 
RV: TGA TGT CTG CAG GTA CAC AAG 
NFKB1 FW: GTG ACA GGA GAC GTG AAG ATG 
RV: CAA GTT GAG AAT GAA GGT GGA TG 
NFKB2 FW: GAA GCC AGT CAT CTC CCA G 
RV: CAT CTT TCT GCA CCT TGT CAC 
 
PTX cytotoxicity and combinatory approach in 
vitro 
Wild type BXPC3 and selected BXPC3 clones 
were tested in a dose-response assay for sensitivity to 
PTX treatment using MTS metabolic assay with the 
same protocol reported above. Tested concentrations 
were 0.1, 0.5, 1, 5, 10, 50, 100 and 500 ng/mL. 
The BXPC3 PA clone was challenged in a 
combinatory treatment by both sTRAIL-containing 
supernatants and Paclitaxel. In detail, BXPC3 PA cells 
were seeded in a 12-wells multiwell plate at the 
density of 15000 cells/cm2 in complete medium. The 
next day, the medium was replaced with AD-MSC 
EMPTY-derived supernatant either with or without 
the addition of 5 ng/mL PTX. This concentration was 
chosen based on dose-response result which showed 
50% metabolic inhibition at this dose. After 24 h of 
pre-treatment, wells were washed with PBS and the 
medium was replaced with sTRAIL-containing supe-
rnatant or AD-MSC EMPTY-derived supernatant, also 
adding PTX if present during pre-treatment. Four 
experimental conditions were thus obtained: AD- 
MSC EMPTY-derived conditioned medium (“EMPTY 
CM”), sTRAIL-containing conditioned medium 
(“sTRAIL CM”), AD-MSC EMPTY-derived condition-
ed medium plus PTX (“EMPTY CM+PTX”), sTRAIL- 
containing conditioned medium plus PTX (“sTRAIL 
CM+PTX”). After another 24 h incubation, death rate 
was assessed by PI and Annexin V double staining as 
reported above. In an alternative experimental setting 
without pre-treatment, cells were directly treated as in 
the four conditions stated above for 24 h and then 
stained with PI and Annexin V to assess mortality. 
NFkB-inhibition mediated cytotoxicity and 
sTRAIL combinatory approach 
BXPC3 PA clone was tested in a dose-response 
assay for sensitivity to a known NFkB-inhibitor, such 
as dehydroxymethylepoxyquinomicin (DHMEQ, 
MedchemExpress, NJ, USA). Treatment using MTS 
metabolic assay was performed with the same 
protocol reported above. Tested concentrations were 
1, 5, 10, 15, 20, 25, 40, 50 µg/mL for 48 h. Moreover, 
BXPC3 PA cells were also challenged in a 
combinatory treatment by both sTRAIL-containing 
supernatants and 20 µg/mL DHMEQ with the same 
protocol described above for the combination with 
PTX. 
In vivo studies 
To further strengthen the rationale of the 
combined approach, an ectopic animal model of 
pancreatic cancer was established in nude mice. 28 
female 6 weeks-old CD-1 nude mice from Charles 
River (Charles River Laboratories Italia SRL, Lecco, 
Italy) were housed at 12 h light, 12 h dark cycle with 
no restrictions on food and water supply. The animals 
were implanted subcutaneously with 2 million BXPC3 
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PA cells. Absence of mycoplasma contamination was 
tested on BXPC3 cells before in vivo use using the 
MycoAlert Mycoplasma Detection Kit (Lonza, 
Verviers, Belgium). One week after cell implantation, 
tumour mass was palpable sub cutis and the animals 
were randomly divided into 4 groups for treatment: 
the control group received no treatment; the “MSC 
sTRAIL” group received weekly peri-tumoral inject-
ion of 1 million AD-MSC sTRAIL in 200 μl PBS; the 
“Nab-PTX” group received weekly intra-peritoneal 
injection of 20 mg/kg PTX (corresponding to 200 
mg/kg of Abraxane, Celgene Italia, Milan, Italy) in 
200 μl PBS; the “MSC sTRAIL+Nab-PTX” group 
received Nab-PTX treatment followed by AD-MSC 
sTRAIL inoculum on the following day. Starting from 
day 1 post-injection, the health of the animals was 
monitored regularly, and weight and tumour size 
were measured weekly. Tumour volume was 
estimated according to the formula: Volume = (length · 
width2) / 2. Treatments were repeated four times, the 
animals were then euthanized, and tumour masses 
removed for histologic evaluation. All procedures 
were conducted in accordance with the institutional 
and national guidelines and under approved 
protocols by the Local Ethical Committee on Animal 
Experimentation and by the Italian Ministry of 
Health. 
Histology 
Formalin-fixed, paraffin-embedded tumour 
sections were evaluated by hematoxylin-and-eosin 
staining (Sigma Aldrich). For immunohistochemistry, 
sections were retrieved in citrate buffer (pH 6) for 15 
min and incubated overnight at 4 °C with 
anti-cytokeratin 7 (CK-7) SP52 antibody (Ventana, 
Tucson, AZ, USA) or Cleaved Caspase-3 (Asp175) 
(5A1) antibody (Cell Signaling Technology, Danvers, 
MA, USA). Slides were then incubated with a 
biotinylated goat anti-rabbit IgG (H+L) (1:200; Vector 
Laboratories, Burlingame, CA) for 1h at room 
temperature. Negative controls were run simultan-
eously omitting primary antibody while incubating 
with buffer. Staining was performed and visualized 
by 3,3’-diaminobenzidine (DAB, Vector Laboratories). 
All slides were counterstained with Harris 
hematoxylin (Bio Optica, Milan, Italy). 
Statistical analyses 
Data have been analysed using Microsoft Excel 
2010 (Microsoft Corporation, Redmond, WA, USA) 
and are expressed as mean values ±SEM unless 
otherwise noted. Unpaired 2-tailed Student’s T-test 
was used considering p≤0.05 as statistically signify-
cant. Anova test was performed using Prism software 
(GraphPad Software Inc., La Jolla, CA, USA) 
considering p≤0.05 as statistically significant. 
Results 
Selected BXPC3 cell lines demonstrate a 
remarkable tolerance to TRAIL-mediated 
killing 
To generate TRAIL resistant clones, parental 
BXBC3 WT cells were treated by sTRAIL-containing 
supernatants either continuously or intermittently for 
several weeks, as represented in Figure 1A. Superna-
tants, obtained from gene modified AD-MSC, 
contained an average of 407±97 pg/mL sTRAIL. After 
10 hits of pulsed selection or 10 weeks of continuous 
treatment, selected BXPC3 clones (n=4: CA and CB for 
continuous selection, PA and PB for pulsed selection) 
were tested for resistance to sTRAIL in MTS assay 
compared with wild type BXPC3. All selected BXPC3 
clones demonstrated between 2 and 30-fold increase 
in sTRAIL tolerance compared to wild type BXPC3. 
These differences were significantly marked in the 
pulsed selection group with the BXPC3 PA clone as 
the most resistant. Particularly, inhibition rate for 
wild type BXPC3 was 41.8±0.8% while for resistant 
clone PA it was 1.3±4.5%, 2.4±3.2% for PB, 8.6±1.5% 
for CA and 22.5±2.9% for CB (Figure 1B). Moreover, 
we performed a dose-response assay to verify 
whether the resistant BXPC3 cells could be additionn-
ally cross-resistant to the recombinant form of TRAIL. 
All tested clones revealed an inhibition rate that 
reached a plateau at 500 ng/mL rhTRAIL (Figure 1C). 
Among resistant clones, again the BXPC3 PA clone 
showed the highest tolerance, with a maximum 
inhibition of 27.1±1.6%. On the contrary, CB clone had 
a maximum inhibition rate of 80.6±0.7%, very close to 
the 83.5±0.7% of wild type BXPC3. CA and PB clones 
showed an intermediate resistance with a growth 
inhibition of 72.8±1.0% and 60.6±1.5%, respectively. 
These data indicated the BXPC3 PA clone as the most 
resistant to either sTRAIL-containing supernatant or 
rhTRAIL, thereby prompting its use for further 
analyses. 
BXPC3 resistance to TRAIL is led by 
overexpression of pro-survival genes 
To assess whether the lower response to TRAIL 
on selected BXPC3 clones was due to an impaired 
expression of TRAIL surface receptors, cells were 
analysed by FACS (Figure 1D). Expression of TRAIL 
functional receptors was statistically similar between 
all tested samples, with low DR4 expression ranging 
from 1.8±0.6% in the CA clone, to 5.1±1.3% in the CB 
clone and 3.8±0.5% for wild type BXPC3. On the 
contrary, DR5 levels were consistently higher in all 
samples with 81.3±7.0% in WT, 96.2±1.4% in PA, 
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93.5±3.3% in PB, 90.0±6.2% in CA and 88.8±4.9% in 
CB. A modest although not statistically significant 
increase in DcR2 decoy receptor was observed in 
selected clones (14.5±1.2% in CA, 16.2±3.9% in PB, 
17.3±6.9% in PA and 20.2±5.3% in CB) compared with 
wild type BXPC3 (6.2±2.3%). Finally, positivity of 
decoy receptor DcR1 was very low in all tested 
samples, ranging from 1% to 2% (Figure 1D). Having 
demonstrated that the resistance to TRAIL was not 
due to the selection of clones with down-regulated 
receptors expression or an increase in decoy levels, we 
began to address whether the resistance could be due 
to the regulation of downstream factors. TRAIL 
resistance is reported in relationship to a series of key 
pro-survival genes [28], therefore the most resistant 
clone BXPC3-PA was compared with WT cells by 
microarray analysis to identify candidate transcripts 
to be further investigated (Supplementary Table S1). 
Differential expression of selected genes involved in 
TRAIL apoptotic pathway [29] is summarized in 
Table 2. Subsequent qPCR on a subset of 
differentially-expressed pro-survival genes showed a 
significant 2- to 4-fold increase in expression of 
BCL-XL, cFLIP, XIAP, NFKB1 and NFKB2 compared 
to WT cells (Figure 1E). These data depicted a 
pro-survival pattern that justifies the outlined BXPC3 
resistance, suggesting how combinatory strategy 
based on agents targeting one or more of these 
pro-survival genes could be effective in rescuing the 
BXPC3 sensitivity to TRAIL. 
 
Table 2. Summarized differential expression of selected TRAIL 
pathway-related genes from microarray analysis (from 
Supplementary Table S1) of the TRAIL resistant BXPC3 PA versus 
BXPC3 WT parental cells 
 
afamily of genes; bcomponents of a molecular complex 
 
In vitro Paclitaxel treatment induces 
cytotoxicity in wild type and resistant BXPC3 
clones counteracting sTRAIL resistance 
Considering the role of PTX in hindering 
TRAIL-related pro-survival pathways [30–32], we 
sought to challenge all resistant BXPC3 clones with 
PTX in comparison with wild type cells. Dose- 
response assay by MTS showed a similar sensitivity of 
both wild type and resistant BXPC3 clones after 72 h 
PTX treatment (Figure 2A). In particular, 50% 
inhibition was obtained at PTX dose of 5 ng/mL and a 
plateau was reached after 50 ng/mL in all samples, 
indicating that the TRAIL resistant pattern was not 
cross-influencing with a PTX apoptosis induction, 
further justifying its role as sensitizer agent for 
sTRAIL. 
Therefore, a combined treatment of sTRAIL- 
containing supernatant with 5 ng/mL PTX for 24 h 
was introduced, generating a significant increase in 
apoptosis of BXPC3 PA clone (51.8±2.0%) compared 
either with sTRAIL-containing supernatant alone 
(16.0±1.5%) or PTX alone (27.0±3.6%) and suggesting a 
synergy between the two agents (Figure 2B). 
A pre-treatment strategy was additionally 
developed by incubating BXPC3 cells with PTX 24 h 
prior to the treatment with sTRAIL-containing 
supernatant. This setting again confirmed the 
sensitizing effect of PTX which was found to be even 
increased with 65.8±1.8% death rate in combination 
with sTRAIL-containing supernatant, 28.1±1.2% with 
PTX only and 16.1±2.5% with AD-MSC sTRAIL 
supernatant only (Figure 2C). Similar in vitro results 
have been obtained by Nab-PTX that was then 
introduced in the in vivo model for its significantly 
better toxicity and delivery profile versus PTX [34] 
(Supplementary Figure S1). 
Having accounted for the combinatory impact of 
sTRAIL and PTX against artificially-induced TRAIL 
resistance, we wanted to additionally challenge that in 
spontaneously TRAIL-resistant PDAC cell lines 
expressing TRAIL receptors. Therefore, CFPAC-1 and 
PaTu 8988t (PaTu) cell lines were selected and treated 
with sTRAIL and PTX alone or in combination 
(Supplementary Figure S3). Collectively these data on 
additional cell lines reinforce the rationale of a 
combined therapy with Nab-PTX as a sensitizing 
agent for TRAIL-resistant tumours while also 
highlighting the high variability of PC tumours which 
showed variegated responses and demand for a 
deeper investigation on effective doses. 
Considering the previously mentioned genes 
involved in sTRAIL resistance (Figure 1E), we began 
to identify the molecular mechanisms that may be 
involved in the PTX sensitization observed in the 
BXPC3 clone. Interestingly, the expression of pro- 
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survival genes (BCL-XL, cFLIP, XIAP, NFKB1 and 
NFKB2) significantly dropped after PTX treatment to 
levels close to or lower than wild type cells, 
suggesting a restoring action by PTX in sTRAIL 
resistant cells (Figure 2D). To further strengthen this 
observation, we combined sTRAIL treatment with 
pharmacological inhibition of NFkB by incubation 
with DHMEQ. Cells were treated with DHMEQ alone 
in a dose response assay, showing a progressive 
inhibition of tumour cell metabolism reaching a 
plateau from the dose of 25 µg/mL (Figure 3A). We 
then treated sTRAIL-resistant cells with 20 µg/mL of 
DHMEQ along with sTRAIL CM in a combined 
treatment (Figure 3B). We observed a 31.4±2.7% cell 
death when cells were incubated with DHMEQ alone 
which dramatically rose to 92.6±0.8% in the combined 
setting, thus confirming the role of NFkB in the TRAIL 
resistance pathway. Control death rate was 15.2±2.2% 
while sTRAIL conditioned medium alone led to 
21.9±1.2% cell death. 
AD-MSC sTRAIL and Nab-PTX combined 
treatment has a potent anti-tumour effect on 
tumour size and vitality 
Based on in vitro findings, a xenotransplant 
model was established to challenge the potential of 
AD-MSC sTRAIL and Nab-PTX combined treatment. 
Mice bearing BXPC3 PA clones were treated weekly 
by 20 mg/kg PTX i.p. and/or peri-tumoral injection of 
1 million AD-MSC sTRAIL. Tumour volume monit-
oring confirmed that BXPC3 PA clone maintains 
sTRAIL resistance in vivo and, after 35 days from 
implantation, tumours from the group treated by 
AD-MSC sTRAIL were similar to untreated control 
mice (Figure 4A and 4B).  
Nab-PTX treatment was effective in counteract-
ing pancreatic cancer development and, most inter-
estingly, its combination with AD-MSC-delivered 
sTRAIL demonstrated a robust anti-cancer effect 
compared to all other conditions. BXPC3 PA tumour 
size in the combinatory group was 2 times smaller 
versus both AD-MSC sTRAIL alone and the untreated 
controls, while a 1.5 fold decrease was observed 
against the Nab-PTX only group (Figure 4A and 4B). 
Histological studies confirmed the potential of 
the strategy with a hematoxylin and eosin staining 
showing a compact structure in both untreated 
control and AD-MSC sTRAIL groups with islets of 
small pancreatic cancer cells surrounded by a dense 
stromal network (Figure 4C upper and lower rows). 
Nab-PTX group showed a looser and less organized 
architecture with areas characterized by an increase in 
the stromal compartment as against the pancreatic 
cancer areas. It is notable how the MSC 
sTRAIL+Nab-PTX treated xenotransplants showed a 
dramatic reduction in pancreatic cancer component 
with large holes in the histological preparation 
together with an apparent increase in stromal fraction. 
Moreover, an immunohistochemical staining for 
human Cytokeratin-7 confirmed the morphological 
features described (Figure 4D), in particular the 
relationship between pancreatic cancer and stroma in 
the group treated by the combinatory strategy. 
Finally, the staining for cleaved Caspase-3 (Figure 4E) 
showed areas of positive cells particularly evident 
around compromised regions, thus highlighting the 
role of apoptosis in the architecture modifications 
described. Collectively, these findings confirmed the 
in vitro data providing further evidence of a 
taxane-based combinatory approach capable of 
restoring sTRAIL sensitivity within a relevant 
pre-clinical pancreatic cancer model.  
Discussion 
Pancreatic cancer is a highly lethal disease with 
yet limited therapeutic options. The low survival rate 
is connected with a late diagnosis, a high metastatic 
potential and the lack of game changing therapies. In 
this scenario, innovative strategies also based on cell 
and gene therapy are needed. In particular, a deeper 
characterization of the individual patient’s tumour 
coupled with the action of targeted therapies could 
lead to more effective and personalized treatments 
[35,36]. Among these strategies, the employment of 
biological vectors such as cells delivering targeted 
therapeutic agents may allow a greater precision, 
augmenting local compound bioavailability and 
reducing off-target toxicity. 
MSC may represent this paradigm by virtue of 
their immunological characteristics and innate 
migration capacity to inflamed tissues, such as 
tumours [12]. Several studies have shown the 
advantages and efficacy of MSC-based gene therapy, 
and our research focuses on cancer treatment by gene 
modified MSC producing TRAIL variants, showing 
an effect both in vitro and in vivo [17,27]. In these 
settings, cellular vehicles can deliver a single 
compound with pre-clinical evidence of efficacy and 
safety. However, it is well known that a single agent 
delivery, even by innovative tools, may have 
limitations in oncology, and several groups are now 
identifying combinatory schedules in which 
conventional therapies can be combined with new 
therapeutic tools [25]. This is generally done to 
counteract cancer cell resistance prompting the 
combination of different ways of delivery and action 
to improve long-term efficacy.  
We previously demonstrated that TRAIL 
variants delivered by MSC could be effective in 
targeting human pancreatic cancer [17,19,33]. Being 
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aware of the possibility related to TRAIL resistance 
and with the purpose of empowering our gene deliv-
ery, here we originally propose to combine Taxanes as 
known agents against pancreatic cancer [37], with 
AD-MSC delivering sTRAIL in a challenging 
TRAIL-resistant cancer. 
 
Figure 2. Paclitaxel treatment sensitizes resistant BXPC3 to sTRAIL by 
reversing survival pathways (A) PTX dose-response assay for wild type (WT) and 
selected BXPC3 clones by MTS. Cells were treated with a range of concentrations 
of PTX for 72 h. (B) In vitro combined treatment of sTRAIL- containing supernatant 
with PTX. PA clone cells were treated for 24 h with AD-MSC EMPTY derived 
conditioned medium (EMPTY CM) or AD-MSC sTRAIL derived conditioned medium 
(sTRAIL CM) or the same with 5 ng/mL PTX (EMPTY CM+PTX and sTRAIL 
CM+PTX). Death rate was evaluated by PI and Annexin V staining in flow cytometry. 
(C) Pre-treatment strategy included a 24 h incubation with 5 ng/mL PTX for EMPTY 
CM+PTX and sTRAIL CM+PTX groups. The subsequent treatment was performed 
as in B for a further 24 h. (D) Expression of main pro-survival genes by qPCR assay 
on BXPC3 PA after 24 h treatment with 50 ng/mL PTX (BXPC3 PA-PTX) compared 
with untreated cells (BXPC3 PA) and BXPC3 WT as baseline. Data are represented 
as mean±SD. All data are represented as the mean of two independent experiments 
performed in triplicate. * p<0.01; ** p<0.05 with Student’s T-test. 
To generate a TRAIL-resistant pancreatic cancer 
model, we incubated BXPC3 cells with sTRAIL- 
containing supernatants for up to 3 months with 
different schedules to select resistant populations 
mimicking the situation of an induced resistance. The 
clones obtained showed different levels of sTRAIL 
resistance, resulting in a mortality rate 2 to 30 times 
lower than unselected BXPC3 control, with a sTRAIL 
resistance that was more evident in cells obtained 
through discontinuous selection versus samples 
maintained in constant selection. Another possibility 
would have been to work with an intrinsically 
resistant clone or to clonally dilute a BXPC3 cell 
suspension and test individual colonies for resistance 
to sTRAIL [38]. In particular, we focused only on the 
first aspect demonstrating that even naturally TRAIL 
resistant lines (PaTu and CFPAC-1) can be in principle 
sensitized by PTX. However, we have been more 
interested in the induced resistance model that is 
closer to a possible clinical scenario. In particular, 
pulsed selection resembles repeated doses of 
chemotherapy as a clinically relevant schedule and, 
very interestingly, this was the approach capable of 
generating the most sTRAIL resistant pancreatic 
cancer lines.  
Characterization of selected clones included also 
a dose-response assay to determine the resistance 
against the recombinant human form of TRAIL, which 
led to the same results obtained with sTRAIL- 
containing supernatants. In particular, maximum 
mortality rate for non-selected BXPC3 was more than 
80% versus less than 30% for the most resistant clone 
PA, similarly to that reported for pancreatic cancer 
lines constitutively resistant to TRAIL [39]. 
We describe a plateau effect from rhTRAIL 
concentration of 500 ng/mL onwards in all the tested 
samples. On the one hand, this result confirms an 
induced resistance in selected cells, while on the other 
hand, it shows the limits of a rhTRAIL monotherapy 
in vitro, unable to fully eradicate tumour cells and 
suggesting a combination with another compound for 
a better therapeutic profile. 
Reported mechanisms for rhTRAIL resistance in 
vitro included down-regulation of active receptors, 
up-regulation of decoy receptors and desensitization 
of the cell to the apoptotic stimulus [29]. FACS 
analyses revealed that the expression of active 
receptors was similar between all the selected clones 
and wild type cells, collectively characterized by low 
DR4 and high DR5 expression, similarly to other 
pancreatic cancer cell lines [39]. On the contrary, we 
observed an increase in DcR2 receptor that, although 
not statistically significant respect to control, may 
indicate a trend due to a TRAIL counteracting action.  
The most convincing contribution to TRAIL 
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resistance comes from the analyses of key 
pro-survival genes with a relevant increase in 
BCL-XL, cFLIP, XIAP and NFKB1 and 2 versus 
unselected cells. BCL-XL is part of the BCL-2 family of 
molecules, involved in the mitochondrial pathway of 
apoptosis and frequently up-regulated in many 
cancers. It has been shown that its inhibition can 
improve TRAIL sensitivity in several intrinsically 
resistant pancreatic cancer cell lines and here we also 
confirmed its role in a chemotherapy-induced model 
[39]. cFLIP is also a well-known master anti-apoptotic 
regulator frequently overexpressed in malignant cells 
that suppresses TNF-α, Fas-L, and TRAIL-induced 
apoptosis by creating an apoptosis inhibitory complex 
which blocks caspase cascade [40]. XIAP belongs to a 
family of apoptotic suppressor proteins and inhibits 
several members of the caspase family including 
Caspase-3, 7 and 9. Its connection with TRAIL resist-
ance has been demonstrated in several tumours such 
as melanoma, nasopharyngeal carcinoma and 
pancreatic cancer [41–43]. Moreover, a down- 
regulation of XIAP has been shown to sensitize 
pancreatic cancer cells to MSC-delivered sTRAIL [44]. 
Finally, NFkB effectively prevents TRAIL-mediated 
killing in a range of different tumours [45,46] also by 
having a role in the regulation of other pro-survival 
factors such as cFLIP, IAP and Bcl2 family proteins 
[29]. Starting from these considerations, we further 
confirm our observations and those of others about 
the role of NFkB in sTRAIL resistance by showing that 
its inhibition with the potent synthetic agent DHMEQ 
[47] allows a remarkable recovery of sTRAIL 
sensitivity. This early data additionally indicates how 
a more targeted manipulation of that specific pathway 
could empower TRAIL action; future investigations 
will be implemented to further clarify this combin-
atory strategy. Taken together, all these data support 
the notion of a resistance due to the development of a 
pro-survival cellular state involving master 
anti-apoptotic regulators. These findings have also 
been reported by others [29], with the involvement of 
these same genes in rhTRAIL resistance and support 
the relevance of our resistance induction even in the 
presence of sTRAIL released by AD-MSC. 
To overcome the established or native resistance, 
TRAIL refractory cells were treated with PTX. This 
choice was based on its clinical relevance against 
pancreatic cancer and because of its distinct 
mechanism of action with respect to TRAIL 
minimizing the possibility of a cross-resistance. To 
test the most effective dose of PTX alone, we 
performed a dose-response assay with concentrations 
ranging from 0.1 to 500 ng/mL, demonstrating an 
effect starting from 5 ng/mL onwards with no 
difference between wild type and TRAIL-resistant 
BXPC3 cells. A plateau effect was reached with 50 
ng/mL PTX corresponding to 70% of cell inhibition. 
Beside the identification of an effective dose, the assay 
confirmed our hypothesis that mechanisms providing 
protection from TRAIL-induced apoptosis could not 
protect from the PTX action. This is also indirectly 
confirmed by data on the synergy between rhTRAIL 
and using different formulations of the two 
compounds against multiple tumours, including 
pancreatic cancer [32,48,49]. However, to our 
knowledge, this is the first example of a combination 
of a human cell-based TRAIL delivery and PTX in the 
setting of a TRAIL-resistant tumour.  
In vitro combined treatments showed a 
remarkable improvement in cytotoxicity when the 
two compounds were used together either 
simultaneously or in sequential mode. In the latter 
case, the PTX pretreatment before incubation with 
sTRAIL-containing supernatants generated the 
highest cytotoxicity compared with the two agents 
given simultaneously. Interestingly, the mortality due 
to combined protocols has always been higher than 
the sum of the death rate obtainable after single 
treatments, suggesting a synergy in the anti-cancer 
action of the two compounds. 
 
 
Figure 3. Inhibition of NFkB confirms its main role in sTRAIL resistance of 
selected BXPC3. (A) DHMEQ dose-response assay for wild type (WT) and 
selected BXPC3 clones by MTS. Cells were treated with a range of concentrations 
of DHMEQ for 48 h. (B) In vitro combined treatment of sTRAIL-containing 
supernatant with DHMEQ. PA clone cells were treated for 24 h with AD-MSC 
EMPTY derived conditioned medium (EMPTY CM) or AD-MSC sTRAIL derived 
conditioned medium (sTRAIL CM) or the same with 20 µg/mL DHMEQ (EMPTY 
CM+DHMEQ and sTRAIL CM+DHMEQ). Death rate was evaluated by PI and 
Annexin V staining in flow cytometry. All data are represented as the mean of two 
independent experiments performed in triplicate. * p<0.05; ** p<0.01; *** p<0.001; 
**** p<0.0001 with Student’s T-test 
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Figure 4. In vivo impact of combined treatment with MSC sTRAIL and Nab-PTX. (A) Monitoring of tumour volumes during treatment. Nab-PTX was administered 
i.p. with a PTX final concentration of 20 mg/kg once weekly for four weeks (grey arrowheads). AD-MSC sTRAIL were inoculated peri-tumoral the day following Nab-PTX 
treatment (black arrowheads). Tumour volume was calculated from the measurement of tumour diameters. (B) Pictures of representative tumours from each experimental 
group. (C) Representative images of hematoxylin and eosin staining of tumours from the different treatment groups. Stars indicate the stromal bundles, while black 
arrows point to areas of pancreatic cancer tissue damage. Magnification 100x, scale bar 100 μm. (D) Representative images of the IHC staining for the human CK-7 
(brown DAB). CK-7 positive areas represent human PDAC islets. Tumour stroma (black stars), of murine origin, do not show any positivity for CK7 in any group. Again, 
large areas of empty cancer tissues were evident in the combinatory treatment group (black arrows). Magnification 100x, scale bar 100 μm. (E) Representative images 
of IHC staining for cleaved Caspase-3 (brown DAB). Brown elements, indicated by white arrows, represent cells bearing cleaved Caspase-3. Positive cells are more 
frequent in Nab-PTX and MSC sTRAIL+Nab-PTX groups and, in particular, around PC tissue damaged areas (white dotted region). Magnification 100x, scale bar 100μm. 
^ p<0.0001, * p<0.05, § p<0.05 by ANOVA coupled with multiple comparison test.  
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To verify how PTX could restore BXPC3 
sensitivity to TRAIL, we checked gene expression 
after PTX treatment, and noticed a clear turnaround in 
levels of the master anti-apoptotic genes overexpres-
sed in the resistant clones. Their expression returned 
to levels similar to wild type BXPC3 or even less in the 
case of BCL-XL and NFKB1 genes. These findings 
could justify the rescue in sTRAIL sensitivity by PTX 
as also described previously using rhTRAIL [32,48, 
49]. However, this could depict only a part of the 
entire picture and a deeper understanding will be 
needed, with special focus on the synergistic effect of 
the combination. 
The effect of PTX alone or in combination with 
sTRAIL-containing supernatant was investigated also 
on AD-MSC and we were able to confirm previous 
reports of a reduction of AD-MSC metabolic activity 
and proliferation with little impact on viability [50] 
even in the combined approach (Supplementary 
Figure S2). 
The in vivo xenotransplant of pancreatic cancer 
further tested the working hypothesis in a more 
clinical- relevant model introducing PTX in its 
albumin-bound formulation (Nab-PTX). This was 
mainly due to practical reasons; Nab-PTX is easier to 
deliver in virtue of its solubility in saline solution. In 
contrast, formulation with ethanol and castor oil for 
PTX injection has a high viscosity that makes the 
injection difficult, also being dangerous for mice [51]. 
Moreover, Nab formulation better fits with the 
current standard in chemotherapy [4]. 
The peri-tumoral inoculum of MSC sTRAIL was 
always performed the day after Nab-PTX, following 
the in vitro data of a better BXPC3 PA sensitization to 
TRAIL when the drug was delivered 24 h before the 
supernatant incubation and also to minimize the 
impact of PTX on effector cells. Weekly schedule for 
the combined treatment was decided based on our 
previous studies with sTRAIL-delivering MSC and on 
other studies employing PTX in vivo [17,52]. The 
group treated by AD-MSC sTRAIL only developed 
tumour size similar to untreated controls, thus 
confirming that BXPC3 maintain resistance to sTRAIL 
in vivo and indirectly suggesting that, at least in this 
model, MSC action alone is incapable of counteracting 
tumour growth. Cousin et al. originally reported that 
WT adipose MSC could inhibit pancreatic cancer cell 
lines proliferation [53]; however, it may be that the 
sTRAIL resistance of our clones is associated with an 
up-regulation of pro-survival genes that could, in 
turn, also act against the apoptosis induction due to 
MSC themselves. As expected, Nab-PTX treatment 
alone caused a tumour volume reduction associated 
with a decrease of the pancreatic cancer component 
with no change in the desmoplastic reaction that 
apparently seemed even increased, as in vivo 
confirmation of PTX efficacy on pancreatic cancer, 
regardless of TRAIL-resistance. 
The combined treatment showed the highest 
reduction in tumour volume in line with the 
histological analyses, clearly indicating the impair-
ment of tumour tissue in treated samples impacting 
both the pancreatic cancer cells and their stromal 
component.  
Translating these findings to a future clinical 
scenario, this study favourably supports the 
combination of cell mediated TRAIL therapy with 
PTX either in up-front treatment or in case of an 
established TRAIL resistance. To conclude, given the 
complexity of adenocarcinomas and their ability to 
adapt and relapse, synergy between different 
strategies including standard treatments, targeted 
therapy and immunotherapy should be pursued to 
improve disease outcome, in particular in still deadly 
conditions, such as pancreatic adenocarcinoma. 
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